Home
AKBA
AKBA News

Latest Akebia Therapeutics Inc. (AKBA) News on June 5, 2025

Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology

GlobeNewswire

a day ago

Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

3 days ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025

GlobeNewswire

8 days ago

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025

Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025

GlobeNewswire

9 days ago

Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

GlobeNewswire

23 days ago

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Akebia Therapeutics First Quarter 2025 Earnings: Beats Expectations

Simply Wall St.

a month ago

Akebia Therapeutics First Quarter 2025 Earnings: Beats Expectations

Akebia Therapeutics Inc (AKBA) Q1 2025 Earnings Call Highlights: Strong Revenue Performance and ...

GuruFocus.com

a month ago

Akebia Therapeutics Inc (AKBA) Q1 2025 Earnings Call Highlights: Strong Revenue Performance and ...

Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates

Zacks

a month ago

Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates

Associated Press Finance

a month ago

Akebia Therapeutics: Q1 Earnings Snapshot

Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

GlobeNewswire

a month ago

Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Earnings To Watch: Akebia Therapeutics Inc (AKBA) Reports Q1 2025 Result

GuruFocus.com

a month ago

Earnings To Watch: Akebia Therapeutics Inc (AKBA) Reports Q1 2025 Result

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a month ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy?

Zacks

a month ago

Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy?

Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights

GlobeNewswire

a month ago

Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights

MT Newswires

a month ago

Leerink Partners Initiates Coverage on Akebia Therapeutics With Outperform Rating, $7 Price Target

Why You Shouldn't Bet Against Akebia Therapeutics (AKBA) Stock

Zacks

2 months ago

Why You Shouldn't Bet Against Akebia Therapeutics (AKBA) Stock

US High Growth Tech Stocks to Watch in 2023

Simply Wall St.

2 months ago

US High Growth Tech Stocks to Watch in 2023

MT Newswires

2 months ago

Akebia Therapeutics Says EMA Panel Recommends Approval of Xoanacyl for Chronic Kidney Disease Treatment

Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa

GlobeNewswire

2 months ago

Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

GlobeNewswire

2 months ago

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering

Zacks

2 months ago

Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering

Accenture reports Q2 beat, Apple TV+ losing $1B annually: Morning Buzz

TipRanks

2 months ago

Accenture reports Q2 beat, Apple TV+ losing $1B annually: Morning Buzz

Why Akebia Therapeutics Inc. (AKBA) Went Down On Thursday?

Insider Monkey

2 months ago

Why Akebia Therapeutics Inc. (AKBA) Went Down On Thursday?

MT Newswires

3 months ago

Top Midday Decliners

MT Newswires

3 months ago

Top Premarket Decliners

MT Newswires

3 months ago

Akebia Therapeutics Prices $50 Million Public Offering

Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

GlobeNewswire

3 months ago

Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

Is Akebia Therapeutics (AKBA) the Best Stock to Invest in for a Stock Market Game?

Insider Monkey

3 months ago

Is Akebia Therapeutics (AKBA) the Best Stock to Invest in for a Stock Market Game?

Akebia Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire

3 months ago

Akebia Therapeutics Announces Proposed Public Offering of Common Stock

US$7.83 - That's What Analysts Think Akebia Therapeutics, Inc. (NASDAQ:AKBA) Is Worth After These Results

Simply Wall St.

3 months ago

US$7.83 - That's What Analysts Think Akebia Therapeutics, Inc. (NASDAQ:AKBA) Is Worth After These Results

Akebia Therapeutics Inc (AKBA) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines ...

GuruFocus.com

3 months ago

Akebia Therapeutics Inc (AKBA) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines ...

Thomson Reuters StreetEvents

3 months ago

Q4 2024 Akebia Therapeutics Inc Earnings Call

MT Newswires

3 months ago

Sector Update: Health Care Stocks Slipping Late Afternoon

MT Newswires

3 months ago

Akebia Therapeutics Shares Fall After Q4 Results

Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates

Zacks

3 months ago

Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates

Associated Press Finance

3 months ago

Akebia Therapeutics: Q4 Earnings Snapshot

Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update

GlobeNewswire

3 months ago

Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update

Exploring High Growth Tech Stocks In The US Market

Simply Wall St.

3 months ago

Exploring High Growth Tech Stocks In The US Market

Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

GlobeNewswire

3 months ago

Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

3 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

4 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia announces ‘multiple positive business updates’

TipRanks

5 months ago

Akebia announces ‘multiple positive business updates’

Akebia Therapeutics Announces Multiple Positive Business Updates

PR Newswire

5 months ago

Akebia Therapeutics Announces Multiple Positive Business Updates

New Strong Sell Stocks for January 3rd

Zacks

5 months ago

New Strong Sell Stocks for January 3rd

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

5 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

High Growth Tech Stocks To Watch In December 2024

Simply Wall St.

6 months ago

High Growth Tech Stocks To Watch In December 2024

Investors in Akebia Therapeutics (NASDAQ:AKBA) have unfortunately lost 73% over the last five years

Simply Wall St.

6 months ago

Investors in Akebia Therapeutics (NASDAQ:AKBA) have unfortunately lost 73% over the last five years

Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

PR Newswire

6 months ago

Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

New Strong Sell Stocks for December 5th

Zacks

6 months ago

New Strong Sell Stocks for December 5th

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

6 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis

PR Newswire

6 months ago

U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis

New Strong Sell Stocks for November 27th

Zacks

6 months ago

New Strong Sell Stocks for November 27th

Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

PR Newswire

6 months ago

Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease

PR Newswire

7 months ago

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease

Akebia Therapeutics to Present at the Jefferies London Healthcare Conference

PR Newswire

7 months ago

Akebia Therapeutics to Present at the Jefferies London Healthcare Conference

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50

Simply Wall St.

7 months ago

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50

Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...

GuruFocus.com

7 months ago

Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...

Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates

Zacks

7 months ago

Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates

Associated Press Finance

7 months ago

Akebia Therapeutics: Q3 Earnings Snapshot

Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

PR Newswire

7 months ago

Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

7 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights

PR Newswire

7 months ago

Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights

High Growth Tech Stocks to Watch in October 2024

Simply Wall St.

7 months ago

High Growth Tech Stocks to Watch in October 2024

MT Newswires

7 months ago

Akebia Therapeutics Signs Contract to Expand Vafseo Access for Patients on Dialysis; Shares Rise

Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

PR Newswire

7 months ago

Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024

PR Newswire

8 months ago

Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024

MT Newswires

8 months ago

Akebia Therapeutics Says Vafseo Granted TDAPA Reimbursement

CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025

PR Newswire

8 months ago

CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025

Akebia Therapeutics Inc (AKBA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...

GuruFocus.com

8 months ago

Akebia Therapeutics Inc (AKBA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...

MT Newswires

8 months ago

Akebia Therapeutics Enters Multi-Year Supply Contract With U.S. Renal Care for Vafseo

Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

PR Newswire

8 months ago

Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Path To Profitability

Simply Wall St.

8 months ago

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Path To Profitability

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

8 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis

PR Newswire

9 months ago

Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

9 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?

Zacks

9 months ago

Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?

Here's Why You Should Consider Buying Akebia (AKBA) Stock

Zacks

9 months ago

Here's Why You Should Consider Buying Akebia (AKBA) Stock

Akebia Therapeutics to Present at Upcoming Investor Conferences

PR Newswire

9 months ago

Akebia Therapeutics to Present at Upcoming Investor Conferences

Zacks Industry Outlook Highlights Corcept, Amneal, Bioventus, Foghorn and Akebia

Zacks

10 months ago

Zacks Industry Outlook Highlights Corcept, Amneal, Bioventus, Foghorn and Akebia

5 Small Drug Stocks to Buy as Innovation Reaches Peak

Zacks

10 months ago

5 Small Drug Stocks to Buy as Innovation Reaches Peak

Are Medical Stocks Lagging Acrivon Therapeutics, Inc. (ACRV) This Year?

Zacks

10 months ago

Are Medical Stocks Lagging Acrivon Therapeutics, Inc. (ACRV) This Year?

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Just Reported And Analysts Have Been Lifting Their Price Targets

Simply Wall St.

10 months ago

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Just Reported And Analysts Have Been Lifting Their Price Targets

Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates

Zacks

10 months ago

Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates

Associated Press Finance

10 months ago

Akebia Therapeutics: Q2 Earnings Snapshot

Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

PR Newswire

10 months ago

Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights

PR Newswire

10 months ago

Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

10 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics to Present at Upcoming Investor Conferences

PR Newswire

10 months ago

Akebia Therapeutics to Present at Upcoming Investor Conferences

MT Newswires

a year ago

Akebia Regains Full Rights to Sell Vafseo Tablets in US After Ending Licensing Deal With CSL Vifor

Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets

PR Newswire

a year ago

Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

a year ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

PR Newswire

a year ago

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

MT Newswires

a year ago

Akebia Therapeutics Names Erik Ostrowski CFO, CBO

Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer

PR Newswire

a year ago

Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer

Further weakness as Akebia Therapeutics (NASDAQ:AKBA) drops 16% this week, taking five-year losses to 80%

Simply Wall St.

a year ago

Further weakness as Akebia Therapeutics (NASDAQ:AKBA) drops 16% this week, taking five-year losses to 80%

Industry Report: The Cannabis Company that Soared Nearly 100% This Year: What's Behind InterCure's Surge

ACCESSWIRE

a year ago

Industry Report: The Cannabis Company that Soared Nearly 100% This Year: What's Behind InterCure's Surge

Russia is doubling down on its de-dollarization efforts as Putin calls to reduce use of 'toxic' currencies

Business Insider

a year ago

Russia is doubling down on its de-dollarization efforts as Putin calls to reduce use of 'toxic' currencies

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting

GlobeNewswire

a year ago

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting

Nvidia May Be an Exciting Stock, but Its 10-for-1 Stock Split -- Like Most Stock Splits -- Is a Nothing Burger

Motley Fool

a year ago

Nvidia May Be an Exciting Stock, but Its 10-for-1 Stock Split -- Like Most Stock Splits -- Is a Nothing Burger

Share on Social Networks: